Quality management in analytical R&D in the pharmaceutical industry: Building quality from GLP

被引:0
|
作者
F. Geijo
机构
[1] R&D Quality Assurance Unit,
[2] Ipsen Pharma Ctra. Laureà Miró,undefined
[3] 395 St. Feliu de Llobregat,undefined
[4] 08980 Barcelona,undefined
[5] Spain e-mail: fernando.geijo@beaufour-ipsen.com Tel.: +34-936-858 125 Fax: +34-936-851 011,undefined
来源
关键词
Key words Quality management; Good laboratory practice; EN 45001; Analytical research and development; Pharmaceutical research and development;
D O I
暂无
中图分类号
学科分类号
摘要
 The pharmaceutical industry is one of the most regulated activity sectors. The regulation includes specific quality systems such as good laboratory practice (GLP), good clinical practice (GCP) and good manufacture practice (GMP). The principles of GLP mainly cover the formal quality aspects of a procedure and do not evaluate the technical aspects in depth. On the other hand, EN 45001 accreditation covers technical performance and is not suitable for pharmaceutical research and development (R&D) as it is almost impossible to comply with the requirements of the European standard in the pharmaceutical environment. The challenge to the pharmaceutical industry is, therefore, to develop quality systems, compatible with GLP principles, that not only cover formal quality items but also ensure good scientific and technical performance. An implementation process focused on real quality improvement is the best way to achieve this objective, culminating in formal recognition of the quality system by third-party assessment.
引用
收藏
页码:16 / 20
页数:4
相关论文
共 50 条